CN1282467C - Medicine for treating coronary disease and stenocardia and its preparation method - Google Patents
Medicine for treating coronary disease and stenocardia and its preparation method Download PDFInfo
- Publication number
- CN1282467C CN1282467C CN 03134404 CN03134404A CN1282467C CN 1282467 C CN1282467 C CN 1282467C CN 03134404 CN03134404 CN 03134404 CN 03134404 A CN03134404 A CN 03134404A CN 1282467 C CN1282467 C CN 1282467C
- Authority
- CN
- China
- Prior art keywords
- portions
- oil
- medicine
- gelatin
- soybean
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 9
- 206010002383 Angina Pectoris Diseases 0.000 title abstract description 12
- 229940079593 drug Drugs 0.000 title description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 25
- 108010010803 Gelatin Proteins 0.000 claims abstract description 21
- 229920000159 gelatin Polymers 0.000 claims abstract description 21
- 239000008273 gelatin Substances 0.000 claims abstract description 21
- 235000019322 gelatine Nutrition 0.000 claims abstract description 21
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 14
- 239000003549 soybean oil Substances 0.000 claims abstract description 14
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 14
- 239000012153 distilled water Substances 0.000 claims abstract description 12
- 229930182470 glycoside Natural products 0.000 claims abstract description 12
- 150000002338 glycosides Chemical class 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019482 Palm oil Nutrition 0.000 claims abstract description 11
- 239000002540 palm oil Substances 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims abstract description 10
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 9
- 239000008347 soybean phospholipid Substances 0.000 claims abstract description 9
- 239000006187 pill Substances 0.000 claims abstract description 7
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 6
- 238000010438 heat treatment Methods 0.000 claims abstract description 6
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 5
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims abstract description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000003825 pressing Methods 0.000 claims abstract description 5
- 239000000084 colloidal system Substances 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000003292 glue Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 229930003944 flavone Natural products 0.000 claims description 11
- 150000002213 flavones Chemical class 0.000 claims description 11
- 235000011949 flavones Nutrition 0.000 claims description 11
- 229920002545 silicone oil Polymers 0.000 claims description 7
- 239000007766 cera flava Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 3
- 238000010410 dusting Methods 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 241000219780 Pueraria Species 0.000 abstract description 3
- 235000013871 bee wax Nutrition 0.000 abstract 4
- 239000012166 beeswax Substances 0.000 abstract 4
- 239000002775 capsule Substances 0.000 abstract 3
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 2
- 229930003935 flavonoid Natural products 0.000 abstract 2
- 150000002215 flavonoids Chemical class 0.000 abstract 2
- 235000017173 flavonoids Nutrition 0.000 abstract 2
- 235000011187 glycerol Nutrition 0.000 abstract 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 abstract 2
- 238000001816 cooling Methods 0.000 abstract 1
- 238000003801 milling Methods 0.000 abstract 1
- 238000005086 pumping Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 22
- 208000002193 Pain Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000007901 soft capsule Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 2
- 241000657480 Crataegus pinnatifida Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000003218 coronary vasodilator agent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 238000006424 Flood reaction Methods 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to medicine for treating coronary disease and angina pectoris, and a preparation method for the medicine. The medicine is composed of the following raw materials by weight portions: 4 to 60 portions of pueraria root total flavonoid, 1 to 30 portions of hawkthorn extract, 0.4 to 10 portions of gynostemma pentaphylla total glycosides, 5 to 100 portions of soybean oil, 0.1 to 3 portions of beeswax, 0.4 to 10 portions of hydrogenated palm oil, 0.2 to 5 portions of soybean phospholipid, 0.01 to 0.5 portion of methyl silicone oil, 8 to 150 portions of gelatin, 3 to 80 portions of glycerin, 8 to 150 portions of distilled water and 0.01 to 0.8 portion of ethylparaben. The preparation method comprises: preparing a proper amount of distilled water, gelatin, glycerin and ethylparaben into a capsule solution; adding a definite amount of beeswax and hydrogenated palm oil into soybean oil; heating the beeswax, the hydrogenated palm oil and the soybean oil, so the beeswax and the hydrogenated palm oil are completely dissolved in the soybean oil; cooling; adding soybean phospholipid; stirring sufficiently so as to achieve uniformity; gradually adding the medicinal powder of gynostemma pentaphylla total glycosides, hawkthorn extract and pueraria root total flavonoid, and the medicinal powder is sieved by 60 meshes; stirring sufficiently so that the medicinal powder can be blended evenly; milling the medicinal powder twice by a colloid mill; adding methyl silicone oil; placing still; pumping vacuum. When bubbles in medicinal liquor are basically removed, the medicinal liquor is used for standby. The molten capsule solution is used for pressing pills. 580 mg of medicinal liquor is pressed into each pill. The thickness of a capsule skin is about 0.85 to 0.95mm. The pills are formed by a pressing method.
Description
Technical field
The present invention relates to a kind of treatment coronary heart disease and anginal medicine and preparation method thereof.
Background technology
Coronary heart disease and angina pectoris refer to coronary insufficiency, rapid, temporary transient ischemia of cardiac muscle and the caused clinical syndrome of anoxia.Coronary heart disease and anginal Therapeutic Principle are the oxygen consumptions that improves blood supply coronarius and alleviate cardiac muscle, treat atherosclerosis simultaneously.Medicine divides three classes: the first kind is a nitrate preparations, main effect is a coronary artery dilator, reduce resistance, increase outside the blood flow of coronary circulation,, reduce the blood volume of venous return heart also by dilating effect to peripheral vessels, reduce that vascular capacitance, heart are intrinsic pressure, cardiac output and blood pressure, lower the aerobic of heart front and back load and cardiac muscle, thus allevating angina pectoris, and common dosage forms has nitroglycerin, amyl nitrite, pentaerithrityl tetranitrate and isosorbidi dinitras etc.; Second class is a beta-blocker, and blocking-up sympathomimetic amine class is to the stimulation of heart rate and heart contractility, and decreased heart rate brings high blood pressure down, and lowers myocardial contraction and oxygen consumption, thus the outbreak of allevating angina pectoris.The most frequently used preparation has Propranolol, oxprenolol, alprenolol etc.The 3rd class medicine is a calcium channel blocker, and this class drug main will act as the inhibition calcium ion and enter in the cell, also suppresses the effect of calcium ion in the excited excitation-contraction coupling of myocardial cell, thereby inhibition myocardial contraction, reduce myocardium keto consumption, the coronary artery dilator spasm, the blood that improves subendocardiac muscle supplies.Common dosage forms has verapamil, nifedipine, diltiazem etc.In sum, the effect of Drug therapy is to alleviate or reduce angina pectoris attacks, but can not thoroughly solve the coronary stricture problem.For the primary disease acute attack stage is at present clinical can basic controlling, but its catabasis because the course of disease is long, need take medicine for a long time, and the Western medicine toxicity is big, untoward reaction is many.
Summary of the invention
The purpose of this invention is to provide a kind of unique curative effect that has, untoward reaction is little, can take for a long time, the treatment coronary heart disease that tool has no side effect and anginal medicine and preparation method thereof.
Solution of the present invention is based on motherland's medical science to coronary heart disease and angina pectoris and pathogenetic understanding of complication and Therapeutic Principle, with reference to the modern pharmacological research achievement, by traditional Chinese medical science prescription theory, skims the cream off milk.Make its performance blood circulation promoting and blood stasis dispelling, the effect of removing obstruction in the collateral to relieve pain.
Medicine of the present invention is made by following component: (consumption is a weight portion)
Radix Puerariae total flavones 4～60 Fructus Crataegi extracts 1～30 Herb Gynostemmae Pentaphylli total glycosides 0.4～10
Soybean oil 5～100 Cera Flavas 0.1～3 hydrogenated palm oil 0.4～10
Soybean phospholipid 0.2～5 methyl-silicone oil 0.01～0.5 gelatin 8～150
Glycerol 3～80 distilled water 8～150 ethylparabens 0.01～0.8
The optimum weight of medicine of the present invention (part) proportioning is:
Radix Puerariae total flavones 20 Fructus Crataegi extracts 6 Herb Gynostemmae Pentaphylli total glycosides 2 soybean oils 25.4
Cera Flava 0.6 hydrogenated palm oil 2 soybean phospholipids 1 methyl-silicone oil 0.05
Gelatin 40 glycerol 16 distilled water 40 ethylparabens 0.08
Above-mentioned each component is made medicine production method of the present invention is:
1, the preparation of glue: at first gelatin is dissolved, it suck to be expanded, in glycerol, remaining distilled water, putting of ethylparaben glue jar with an amount of distilled water, be heated to 70～80 ℃, mix homogeneously adds expansible gelatin, stir, making it fusion becomes uniform gelatin, opens the vacuum system of glue pot, removes the bubble in the gelatin solution, the limit heating edge boils off the moisture in the gelatin solution, up to viscosity is 28000～32000 millipoises, puts into steady glue bucket and is incubated, standby.
2, with adding quantitative Cera Flava, hydrogenated palm oil in the soybean oil, be heated to 70～80 ℃, make the dissolving fully in soybean oil of above-mentioned two kinds of materials, be cooled to 30～35 ℃, add soybean phospholipid, fully stir, make it even.
3, the Herb Gynostemmae Pentaphylli total glycosides, Fructus Crataegi extract, the Radix Puerariae total flavones medicated powder that added 60 mesh sieves more one by one fully stir, and make its mix homogeneously, cross colloid mill 2 times, add methyl-silicone oil, leave standstill, and evacuation treats that bubble is removed substantially in the medicinal liquid, and is standby.
4, with changing good glue pelleting, every dress 580mg suppresses, and the about 0.85～0.95mm of rubber thickness uses the pressing pill.
Advantage of the present invention is:
1, dosage form advantage:
1.1 soft capsule dosage form is compared with pill with Chinese medicinal tablet, has that disintegrate is fast, bioavailability is high, toxic and side effects is low, and can cover advantages such as bad smell, zest;
1.2 compare characteristics such as useful again prescription just, cost is low with injection;
1.3, be to be used for old people's frequently-occurring disease such as angina pectoris, and soft capsule external form slyness is flexible, swallows after the saliva moistening conveniently, helps old people's medication for this medicine;
1.4 the medicine in the soft capsule dosage form is sealed containing within rubber fully, more help the storage of active, the easy oxidation of character, reductive medicine, especially containing volatile ingredient and determined curative effect for some but material base is indeterminate or the active Chinese patent medicine of character, is the optimum selection dosage form.
2, prescription advantage:
Raising day by day along with modernization of Chinese medicine degree, on the basis of herbal pharmacology and fitochemical studies, pharmaceutically active ingredient or effective site are proved to be definite curative effect and obtain purification in increasing, the present invention arises at the historic moment in this evolution, its scientific and technical content height is modern herbal species.
Fructus Crataegi extract has effects such as blood pressure lowering, coronary artery dilating, heart tonifying, arrhythmia and myocardial ischemia in the prescription; Radix Puerariae total flavones has effects such as the effect of expansion coronary vasodilator, the myocardium coefficient of oxygen utilization of reduction and myocardial oxygen consumption, blood pressure lowering, decreased heart rate, arrhythmia; The Herb Gynostemmae Pentaphylli total glycosides has effects such as blood pressure lowering, blood fat reducing.More than three flavors share common tool coronary artery dilating, blood pressure lowering, effect for reducing blood fat.
For showing the therapeutic effect of medicine of the present invention to angina pectoris, the present invention is through the clinical observation of 98 routine systems, wherein male 61 examples, woman's 37 examples, 39～73 years old age, 60 years old mean age, course of disease June～27 years, wherein light, in, heavier, severe case load is respectively 33 examples, 30 examples, 21 examples, 14 examples, all cases all meet the stagnation of heart-blood standard.
Instructions of taking: oral, one time 2,3 times on the one, treatment time is January, clinical experiment result such as table 1, table 2, table 3.
The fractionated relation of table 1 curative effect and the state of an illness
| Degree | The example number | Produce effects | Effectively | Invalid | Increase the weight of | Total effective rate (%) |
| The slight more heavy degree of moderate | 33 30 21 14 | 23 17 6 3 | 9 8 7 5 | 1 4 5 6 | 0 1 3 / | 97.0 83.3 61.9 57.1 |
By table 1 as seen, light, the moderate angina pectoris curative effect of Drug therapy of the present invention obviously is better than weight degree, severe patient.
The relation that table 2 curative effect and electrocardiogram change
| Total routine number | Produce effects | Effectively | Invalid | Increase the weight of | Total effective rate (%) |
| 98 | 41 | 36 | 18 | 3 | 78.6 |
By table 2 as seen, Drug therapy 98 routine angina pectoris patients of the present invention, wherein 41 routine patient's electrocardiograms roughly recover normally, and 36 routine S-T, T ripple have clear improvement, and it is 78.6% that electrocardiogram improves total effective rate.
Table 3 curative effect with take the variation relation of active remedy time
| 0-3 minute | 3-5 minute | More than 5 minutes | Increase the weight of | |
| (example) treatment back (example) before the treatment | 21 42 | 36 25 | 41 27 | / 4 |
By table 3 as seen, treat among the preceding 98 routine patients, 21 routine patients take pain relief in the active remedy 3 minutes, pain relief in the 36 routine patients 3～5 minutes, and 41 routine patients were alleviated more than 5 minutes; Pain relief in the pain relief in treatment back 42 examples 3 minutes, 25 examples 3～5 minutes, 27 routine patient pain relieves more than 5 minutes have 4 routine patient's state of an illness to increase the weight of, and taking active remedy pain can not alleviate.The state of an illness was obviously alleviated after treatment was described.
Any toxicity and side effect are not found in the clinical use of 98 routine patients, and liver, kidney merit do not have change before and after the treatment.
In sum, medicine of the present invention has blood circulation promoting and blood stasis dispelling, the effect of removing obstruction in the collateral to relieve pain, have coronary artery dilator, increase the coronary vasodilator flow, improve myocardial ischemia-anoxemia, reduce the effect of myocardial oxygen consumption and blood viscosity, the treatment angina pectoris is evident in efficacy, particularly light, moderate is better than weight degree and severe, and it is 78.6% that electrocardiogram is improved total effective rate, is worth clinical expansion to use.
Description of drawings
Fig. 1 is a process for preparing medicine process chart of the present invention.
Specific embodiment
The preparation method of Radix Puerariae total flavones, Fructus Crataegi extract, Herb Gynostemmae Pentaphylli total glycosides is;
1, Radix Puerariae total flavones
This product is the ethanol extraction (total flavones) that wild root Pueraria Iobata (Willd) Ohwi. of leguminous plant extracts, and contains puerarin (C
21H
20O
9) must not be less than 15.0%.
[method for making] gets the Herba Gelsemii Elegantis coarse powder, according to the percolation under fluid extract and extractum (an appendix I of the Chinese Pharmacopoeia nineteen ninety-five version O) item, is solvent with ethanol, floods percolation after 2 days, collects effluent, and decompression recycling ethanol also is condensed into thick paste, the drying of dusting, promptly.
2, Fructus Crataegi extract
This product is 70% ethanol extraction of rosaceous plant Fructus Pyri Pashiae Crataegus pinnatifida Bge var.major N.E.Br. Fructus Crataegi Crataegus pinnatifida Bgede.In 60 ℃ of dryings 6 hours, contain rutin (C
27H
30O
16) must not be less than 2.0%.
[method for making] gets Fructus Crataegi, is ground into coarse powder, adds 6 times of amounts of 70% ethanol, twice of heating and refluxing extraction, each 2 hours, merge extracted twice liquid, filter decompression recycling ethanol, being concentrated into relative density is the extractum of 1.32～1.35 (60 ℃ of heat are surveyed), the drying of dusting, promptly.
3, Herb Gynostemmae Pentaphylli total glycosides is pressed the Ministry of Public Health standard, and standard No. is WS3-Z-006-93 (Z) preparation.
Take by weighing raw material by following proportioning: (unit: gram)
Radix Puerariae total flavones 20 Fructus Crataegi extracts 6 Herb Gynostemmae Pentaphylli total glycosides 2 soybean oils 25.4
Cera Flava 0.6 hydrogenated palm oil 2 soybean phospholipids 1 methyl-silicone oil 0.05
Gelatin 40 glycerol 16 distilled water 40 ethylparabens 0.08
Above-mentioned each component is made medicine production method of the present invention is:
1, the preparation of glue: at first gelatin is dissolved, it is sucked expand with an amount of distilled water.In glycerol, remaining distilled water, putting of ethylparaben glue jar, be heated to 70～80 ℃, mix homogeneously adds expansible gelatin, stir, making it fusion becomes uniform gelatin, opens the vacuum system of glue pot, removes the bubble in the gelatin solution, the limit heating edge boils off the moisture in the gelatin solution, up to viscosity is 28000～32000 millipoises, puts into steady glue bucket and is incubated, standby.
2, with adding quantitative Cera Flava, hydrogenated palm oil in the soybean oil, be heated to 70～80 ℃, make the dissolving fully in soybean oil of above-mentioned two kinds of materials.Be cooled to 30～35 ℃, add soybean phospholipid, fully stir, make it even.
3, the Herb Gynostemmae Pentaphylli total glycosides, Fructus Crataegi extract, the Radix Puerariae total flavones medicated powder that added 60 mesh sieves more one by one fully stir, and make its mix homogeneously.Cross colloid mill 2 times.Add methyl-silicone oil, leave standstill, evacuation treats that bubble is removed substantially in the medicinal liquid, and is standby.
4, with changing good glue pelleting, every dress 580mg suppresses, and the about 0.85～0.95mm of rubber thickness uses the pressing pill.
5, typing is dry: will make soft capsule and place the tumble-dryers inner drying, 20 ℃ ± 2 ℃ of temperature, 95% ethanol flush away soft capsule surface, dry back oil, again soft capsule is placed on hang between dry (20 ℃～25 ℃), and to measure the soft capsule shell moisture be 6%～12%.
6, select: dried soft capsule is checked under the light platform, the failure is rejected.
7, check, packing, promptly.
Claims (2)
1, a kind of treatment coronary heart disease and anginal medicine is characterized in that the medicament of being made by weight by following proportion raw material:
Radix Puerariae total flavones 20 Fructus Crataegi extracts 6 Herb Gynostemmae Pentaphylli total glycosides 2 soybean oils 25.4
Cera Flava 0.6 hydrogenated palm oil 2 soybean phospholipids 1 methyl-silicone oil 0.05
Gelatin 40 glycerol 16 distilled water 40 ethylparabens 0.08
Wherein said Fructus Crataegi extract is to extract by the following method: get Fructus Crataegi, be ground into fine powder, add 6 times of amounts of 70% ethanol, heating and refluxing extraction twice, each 2 hours, merge extracted twice liquid, filter, decompression recycling ethanol is concentrated into relative density and surveys in the time of 60 ℃ and be the extractum of 1.32-1.35, the drying of dusting, promptly.
2, preparing according to claim 1, the method for medicine is:
(1) preparation of glue: at first gelatin is dissolved, it suck to be expanded, in glycerol, remaining distilled water, placing of ethylparaben glue jar with an amount of distilled water, be heated to 70-80 ℃, mix homogeneously adds expansible gelatin, stir, making it fusion becomes uniform gelatin, opens the vacuum system of glue pot, removes the bubble in the gelatin solution, the limit heating edge boils off the moisture in the gelatin solution, up to viscosity is the 28000-32000 millipoise, puts into steady glue bucket and is incubated, standby;
(2) in soybean oil, add quantitative Cera Flava, hydrogenated palm oil, be heated to 70-80 ℃, make the dissolving fully in soybean oil of above-mentioned two kinds of materials, be cooled to 30-35 ℃, add soybean phospholipid, fully stir, make it even;
(3) added Herb Gynostemmae Pentaphylli total glycosides, Fructus Crataegi extract, the Radix Puerariae total flavones medicated powder of 60 mesh sieves more one by one, and fully stirred, and made its mix homogeneously, and crossed colloid mill 2 times, and added methyl-silicone oil, and left standstill, evacuation treats that bubble is removed substantially in the medicinal liquid, and is standby;
(4) with changing good glue pelleting, every dress 580mg suppresses, and the about 0.85-0.95mm of rubber thickness uses the pressing pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03134404 CN1282467C (en) | 2003-07-16 | 2003-07-16 | Medicine for treating coronary disease and stenocardia and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03134404 CN1282467C (en) | 2003-07-16 | 2003-07-16 | Medicine for treating coronary disease and stenocardia and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1475254A CN1475254A (en) | 2004-02-18 |
| CN1282467C true CN1282467C (en) | 2006-11-01 |
Family
ID=34154471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03134404 Expired - Lifetime CN1282467C (en) | 2003-07-16 | 2003-07-16 | Medicine for treating coronary disease and stenocardia and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1282467C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007065539A1 (en) * | 2005-12-06 | 2007-06-14 | Unilever Plc | Extracts of gynostemma and compositions for reducing blood lipid levels |
| CN101703592B (en) * | 2009-10-16 | 2011-12-28 | 西安千禾药业有限责任公司 | Medicament for treating coronary disease and stenocardia and preparation method thereof |
| WO2013007092A1 (en) * | 2011-07-13 | 2013-01-17 | 西安千禾药业有限责任公司 | Medicament for treatment of coronary heart diseases and angina pectoris and preparation method therefor |
| CN103027981B (en) * | 2011-09-28 | 2014-07-23 | 西安千禾药业有限责任公司 | Solid lipid nanoparticle of Gelan Xinning soft capsule for treating coronary heart disease and preparation method and application thereof |
| CN103033586A (en) * | 2011-09-30 | 2013-04-10 | 西安千禾药业有限责任公司 | Detection method of medicament for treating coronary disease and stenocardia |
| CN102885300A (en) * | 2012-09-19 | 2013-01-23 | 无锡市天赐康生物科技有限公司 | Health-care food with blood sugar reducing effect and preparation method thereof |
-
2003
- 2003-07-16 CN CN 03134404 patent/CN1282467C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1475254A (en) | 2004-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038745B (en) | Hypolipidemic traditional Chinese medicine | |
| CN1262299C (en) | Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method | |
| CN1282467C (en) | Medicine for treating coronary disease and stenocardia and its preparation method | |
| CN102362971A (en) | Preparation method and preparation of traditional Chinese medicine for treating coronary heart disease and its effective chemical components | |
| CN1660287A (en) | Capsule for descend of blood fat and preparing method | |
| CN1565467A (en) | Use of cornel and its extract in preparation alpha-glucosidase inhibitor medicine | |
| CN1067258C (en) | Medicinal preparation with extractive from yangtao root and preparing process thereof | |
| CN1279944C (en) | Medicine for treating cardiocerebral vascular system disease and blood supply deficiency, medicine preparing method and preparation | |
| CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1159029C (en) | Blood lipoid regulating medicine and its prepn | |
| CN1453295A (en) | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition | |
| CN101040905A (en) | Medicine made by selfheal for reducing blood sugar | |
| CN1840162A (en) | Compound total extract of compound cape jasmine, ginger and fermented soybean, its preparation and use | |
| CN1232283C (en) | Chinese drugs for treatment of coronary heart disease and angina pectoris | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN1839976A (en) | Compound saponin and flavone extract and its formulation and uses | |
| CN1907357A (en) | Compound pollen essence oral liquid for regulating blood pressure and blood fat and preparation method thereof | |
| CN1850167A (en) | Thirsty-relieving blood-sugar-reducing dropping pills and preparing method | |
| CN1583139A (en) | Preparation of dragon's blood and phospholipin composition | |
| CN1267126C (en) | Chinese medicine for treating coronary heart disease and angina pectoris | |
| CN1586584A (en) | Sinusitis capsule and its preparing method | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN1239159C (en) | Medicine composition for reducing blood fat | |
| CN1314405C (en) | Method for preparing anti-insulin resistant hyperglycemia and hyperlipidemia medicaments using whole herb saponins of Tribulus terrestris | |
| CN1254264C (en) | Chinese traditional medicine for treating rheumatoid arthritis, and preparing technique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: High tech Zone Zhang Bayi Road 710065 Shaanxi city of Xi'an province No. 1 Huixin IBC-B block 11 layer Patentee after: XI'AN CHIHO PHARMACEUTICAL Co.,Ltd. Address before: 710075 Shaanxi city of Xi'an province high tech Zone hi tech Road No. 52 building 17 layer Patentee before: XI'AN CHIHO PHARMACEUTICAL Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: High tech Zone Zhang Bayi Road 710065 Shaanxi city of Xi'an province No. 1 Huixin IBC-B block 11 layer Patentee after: XI' AN CHIHO PHARMACEUTICAL Co.,Ltd. Address before: High tech Zone Zhang Bayi Road 710065 Shaanxi city of Xi'an province No. 1 Huixin IBC-B block 11 layer Patentee before: XI'AN CHIHO PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061101 |